Srini Ramanathan
Corporate Officer/Principal at ROIVANT SCIENCES LTD.
Profile
Srini Ramanathan is currently the Chief Development Officer at Roivant Sciences Ltd.
Prior to this, he worked as the Senior VP-Research & Development Sciences at Horizon Therapeutics Plc.
He holds a doctorate degree from Rutgers State University of New Jersey and a graduate degree from Duquesne University School of Law.
Srini Ramanathan active positions
| Companies | Position | Start |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 2022-05-01 |
Former positions of Srini Ramanathan
| Companies | Position | End |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Training of Srini Ramanathan
| Duquesne University School of Law | Graduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ROIVANT SCIENCES LTD. | Health Technology |
| Private companies | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Srini Ramanathan
